

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

34-04492-02

Docket or Reference number

030-02730

Amendment No. 16

Mercy Hospital
485 West Market Street
Tiffin, OH 44883

In accordance with application dated August 12, 1985, License Number 34-04492-02 is amended as follows:

Conditions 12. and 17. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

W. E. Birmingham, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

G. J. Munoz, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

S. Spendarian, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

C. H. Kim, M.D.

Groups I, II, III and IV
Xenon-133

J. Y. Lee, M.D.

Groups I, II, III and IV
Xenon-133
In vitro studies

J. Cepeda, M.D.

Groups I, II and III
Xenon-133
In vitro studies

D. Park, M.D.

Groups I, II and III
Xenon-133
In vitro studies

G. S. Kang, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

S. Kaosol, M.D.

Group I
In vitro studies

J. J. Suh, M.D.

Groups I, II and III
Xenon-133
In vitro studies

8509110415 850827
REG3 LIC30
34-04492-02 PDR

COPY

2
me30

85 6/28/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

34-04492-02

Docket or Reference number

030-02730

Amendment No. 16

K. C. Rao, M.D.

Groups I, II and III


Xenon-133

Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction or thyroid carcinoma

K. R. Siddiqui, M.D.

Phosphorus-32 (soluble) for
treatment of polycythemia vera,
leukemia and bone metastases
Phosphorus-32 (Colloidal) for
intracavitary treatment

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated May 29, 1984 and August 12, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date August 27, 1985

Original Signed
By Evelyn R. Matson
Materials Licensing Section, Region III

COPY